RxDoctor Payments Data

Karen Luu

Psychiatric/Mental Health · Culver City, CANPI 1215416102

Payments from drug & device makers

$3,121in general payments, 2019–2025

Across 146 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$715
  • AbbVie$467
  • Alkermes, Inc.$374
  • Vanda Pharmaceuticals Inc.$267
  • Neurocrine Biosciences, Inc.$236
  • Otsuka America Pharmaceutical, Inc.$235
  • plus $826 from 10 others

What the payments were for

  • Food & beverage$3,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,121 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$19,531
Medicare patients
25
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate57$191,143
Divalproex Sodium77$6,645
Clozapine68$3,222
Divalproex Sodium ErDivalproex Sodium77$2,633
Olanzapine OdtOlanzapine32$2,348
Aripiprazole23$1,624
Quetiapine Fumarate87$1,436
Risperidone141$1,232
Olanzapine94$1,154
Haloperidol Decanoate31$884
Escitalopram Oxalate95$796
Haloperidol32$635
Mirtazapine52$568
Hydroxyzine Hcl65$552
Benztropine Mesylate76$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$715$191,14357 claims
Almatica Pharma LLCSertraline Hcl$31$31036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Culver City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →